<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">The Clinician</journal-id><journal-title-group><journal-title xml:lang="en">The Clinician</journal-title><trans-title-group xml:lang="ru"><trans-title>Клиницист</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1818-8338</issn><issn publication-format="electronic">2412-8775</issn><publisher><publisher-name xml:lang="en">Publishing House ABV Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">23</article-id><article-id pub-id-type="doi">10.17650/1818-8338-2013-2-14-17</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>REVIEW</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>ОБЗОР</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">IMPACT OF ANGIOTENSIN-CONVERTING ENZYME GENE POLYMORPHISM ON THE DEVELOPMENT OF INSULIN RESISTANCE SYNDROME</article-title><trans-title-group xml:lang="ru"><trans-title>Влияние полиморфизма гена ангиотензинпревращающего фермента на формирование синдрома инсулинорезистентности</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Roitberg</surname><given-names>G. E.</given-names></name><name xml:lang="ru"><surname>Ройтберг</surname><given-names>Г. Е.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Dorosh</surname><given-names>Zh. V.</given-names></name><name xml:lang="ru"><surname>Дорош</surname><given-names>Ж. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Aksenov</surname><given-names>E. V.</given-names></name><name xml:lang="ru"><surname>Аксенов</surname><given-names>Е. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Ushakova</surname><given-names>T. I.</given-names></name><name xml:lang="ru"><surname>Ушакова</surname><given-names>Т. И.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>tatyana_ushakova@medicina.ru</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia</institution></aff><aff><institution xml:lang="ru">ГБОУ ВПО «Российский научно-исследовательский медицинский университет им. Н.И. Пирогова» Минздрава России</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2013-04-15" publication-format="electronic"><day>15</day><month>04</month><year>2013</year></pub-date><volume>7</volume><issue>2</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>14</fpage><lpage>17</lpage><history><date date-type="received" iso-8601-date="2014-07-14"><day>14</day><month>07</month><year>2014</year></date><date date-type="accepted" iso-8601-date="2014-07-14"><day>14</day><month>07</month><year>2014</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2013, Roitberg G.E., Dorosh Z.V., Aksenov E.V., Ushakova T.I.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2013, Ройтберг Г.Е., Дорош Ж.В., Аксенов Е.В., Ушакова Т.И.</copyright-statement><copyright-year>2013</copyright-year><copyright-holder xml:lang="en">Roitberg G.E., Dorosh Z.V., Aksenov E.V., Ushakova T.I.</copyright-holder><copyright-holder xml:lang="ru">Ройтберг Г.Е., Дорош Ж.В., Аксенов Е.В., Ушакова Т.И.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://klinitsist.abvpress.ru/Klin/article/view/23">https://klinitsist.abvpress.ru/Klin/article/view/23</self-uri><abstract xml:lang="en"><p><bold>Objective:</bold> to analyze the distribution of components of insulin resistance (IR) syndrome and to study the frequency of their combinations in relation to the genotypes and allelic variants of the angiotensin-converting enzyme (ACE) gene.</p><p><bold>Subjects and methods.</bold> A group of clinically healthy patients (50 women and 42 men) with different genotypes of the ACE gene was examined.The distribution of IR syndrome components and the frequency of their combinations were analyzed in relation to the genotypes and allelicvariants of the ACE gene.</p><p><bold>Results.</bold> A group of D allele carriers compared to A allele ones showed a pronounced tendency for the frequency of IR to reduce due to thehigher proportion of patients with complete IR syndrome. This observation becomes statistically significant in the assessment of homozygous variants of the ACE gene. At the same time dyslipidemia and hypertension in the presence of IR significantly more frequently occurred in patients with the DD genotype than in those with genotype II.</p><p><bold>Conclusion.</bold> There was a marked predominance of the manifestations of IR syndrome with a complete set of components in the DD genotypicgroup, which confirms the significant strong association between ACE gene polymorphism and IR syndrome.</p></abstract><trans-abstract xml:lang="ru"><p/></trans-abstract><kwd-group xml:lang="en"><kwd>angiotensin-converting enzyme gene polymorphism</kwd><kwd>insulin resistance</kwd><kwd>risk factors</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>полиморфизм гена ангиотензинпревращающего фермента</kwd><kwd>инсулинорезистентность</kwd><kwd>факторы риска</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><citation-alternatives><mixed-citation xml:lang="en">1. The IDF worldwide definition of the metabolic syndrome. http://www.idf.org/metabolic-syndrome.</mixed-citation><mixed-citation xml:lang="ru">The IDF worldwide definition of the metabolic syndrome. http://www.idf.org/metabolic-syndrome.</mixed-citation></citation-alternatives></ref><ref id="B2"><label>2.</label><citation-alternatives><mixed-citation xml:lang="en">2. Anderson P.J., Critchley J.A., Chan J.C. et al. Factor analysis of the metabolic syndrome: obesity vs insulin resistance as the central abnormality. Int J Obes Relat Metab Disord 2001;25(12):1782–8.</mixed-citation><mixed-citation xml:lang="ru">Anderson P.J., Critchley J.A., Chan J.C. et al. Factor analysis of the metabolic syndrome: obesity vs insulin resistance as the central abnormality. Int J Obes Relat Metab Disord 2001;25(12):1782–8.</mixed-citation></citation-alternatives></ref><ref id="B3"><label>3.</label><citation-alternatives><mixed-citation xml:lang="en">3. Carr D.B., Utzschneider K.M., Hull R.L. et al. Intra-abdominal fat is a major determinant of the National Cholesterol Education Program Adult Treatment Panel III criteria for the metabolic syndrome. Diabetes 2004;53(8):2087–94.</mixed-citation><mixed-citation xml:lang="ru">Carr D.B., Utzschneider K.M., Hull R.L. et al. Intra-abdominal fat is a major determinant of the National Cholesterol Education Program Adult Treatment Panel III criteria for the metabolic syndrome. Diabetes 2004;53(8):2087–94.</mixed-citation></citation-alternatives></ref><ref id="B4"><label>4.</label><citation-alternatives><mixed-citation xml:lang="en">4. Метаболический синдром. Под ред. член-корр. РАМН Г.Е. Ройтберга. М.: МЕДпресс-информ, 2007.</mixed-citation><mixed-citation xml:lang="ru">Метаболический синдром. Под ред. член-корр. РАМН Г.Е. Ройтберга. М.: МЕДпресс-информ, 2007.</mixed-citation></citation-alternatives></ref><ref id="B5"><label>5.</label><citation-alternatives><mixed-citation xml:lang="en">5. de Kloet A.D., Krause E.G., Woods S.C. The renin angiotensin system and the metabolic syndrome. Physiol Behav 2010;100(5):525–34.</mixed-citation><mixed-citation xml:lang="ru">de Kloet A.D., Krause E.G., Woods S.C. The renin angiotensin system and the metabolic syndrome. Physiol Behav 2010;100(5):525–34.</mixed-citation></citation-alternatives></ref><ref id="B6"><label>6.</label><citation-alternatives><mixed-citation xml:lang="en">6. Lucius R., Gallinat S., Busche S. et al. Beyond blood pressure: new roles for angiotensin II. Cell Mol Life Sci 1999;56(11–12);1008–19.</mixed-citation><mixed-citation xml:lang="ru">Lucius R., Gallinat S., Busche S. et al. Beyond blood pressure: new roles for angiotensin II. Cell Mol Life Sci 1999;56(11–12);1008–19.</mixed-citation></citation-alternatives></ref><ref id="B7"><label>7.</label><citation-alternatives><mixed-citation xml:lang="en">7. Johnston C.I., Risvanis J. Preclinical pharmacology of angiotensin II receptor antagonists: update and outstanding issues. Am J Hypertens 1997;10(12 Pt 2):306S–10S.</mixed-citation><mixed-citation xml:lang="ru">Johnston C.I., Risvanis J. Preclinical pharmacology of angiotensin II receptor antagonists: update and outstanding issues. Am J Hypertens 1997;10(12 Pt 2):306S–10S.</mixed-citation></citation-alternatives></ref><ref id="B8"><label>8.</label><citation-alternatives><mixed-citation xml:lang="en">8. Chung O., Stoll M., Unger T. Physiologic and pharmacologic implications of AT1 versus AT2 receptors. Blood Press Suppl 1996;5(2):47–52.</mixed-citation><mixed-citation xml:lang="ru">Chung O., Stoll M., Unger T. Physiologic and pharmacologic implications of AT1 versus AT2 receptors. Blood Press Suppl 1996;5(2):47–52.</mixed-citation></citation-alternatives></ref><ref id="B9"><label>9.</label><citation-alternatives><mixed-citation xml:lang="en">9. Mattei M.G., Hubert C., Alhenc-Gelas F. et al. Angiotensin-I converting enzyme gene is on chromosome 17. Cytogenet Cell Genet 1989;51:1041–5.</mixed-citation><mixed-citation xml:lang="ru">Mattei M.G., Hubert C., Alhenc-Gelas F. et al. Angiotensin-I converting enzyme gene is on chromosome 17. Cytogenet Cell Genet 1989;51:1041–5.</mixed-citation></citation-alternatives></ref><ref id="B10"><label>10.</label><citation-alternatives><mixed-citation xml:lang="en">10. Balkau B., Charles M.А., Drivsholm T. et al. Frequency of the WHO metabolic syndrome in European cohorts, and an alternative definition of an insulin resistance syndrome. Diabetes Metab 2002;28(5):364–76.</mixed-citation><mixed-citation xml:lang="ru">Balkau B., Charles M.А., Drivsholm T. et al. Frequency of the WHO metabolic syndrome in European cohorts, and an alternative definition of an insulin resistance syndrome. Diabetes Metab 2002;28(5):364–76.</mixed-citation></citation-alternatives></ref><ref id="B11"><label>11.</label><citation-alternatives><mixed-citation xml:lang="en">11. Метаболический синдром. Под ред. В. Фонсеки. М.: Практика, 2011.</mixed-citation><mixed-citation xml:lang="ru">Метаболический синдром. Под ред. В. Фонсеки. М.: Практика, 2011.</mixed-citation></citation-alternatives></ref><ref id="B12"><label>12.</label><citation-alternatives><mixed-citation xml:lang="en">12. Nesto R.W. The relation of insulin resistance syndromes to risk of cardiovascular disease. Rev Cardiovasc Med 2003;4(6):S11–8.</mixed-citation><mixed-citation xml:lang="ru">Nesto R.W. The relation of insulin resistance syndromes to risk of cardiovascular disease. Rev Cardiovasc Med 2003;4(6):S11–8.</mixed-citation></citation-alternatives></ref><ref id="B13"><label>13.</label><citation-alternatives><mixed-citation xml:lang="en">13. Grundy S.M. Metabolic syndrome: connecting and reconciling cardiovascular and diabetes worlds. J Am Coll Cardiol 2006;47(6):1093–100.</mixed-citation><mixed-citation xml:lang="ru">Grundy S.M. Metabolic syndrome: connecting and reconciling cardiovascular and diabetes worlds. J Am Coll Cardiol 2006;47(6):1093–100.</mixed-citation></citation-alternatives></ref><ref id="B14"><label>14.</label><citation-alternatives><mixed-citation xml:lang="en">14. De Ferranti S.D., Gauvreau K., Ludwig D.S. et al. Prevalence of the metabolic syndrome in American adolescents: findings from the Third National Health and Nutrition Examination Survey. Circulation 2004;110(16):2494–7.</mixed-citation><mixed-citation xml:lang="ru">De Ferranti S.D., Gauvreau K., Ludwig D.S. et al. Prevalence of the metabolic syndrome in American adolescents: findings from the Third National Health and Nutrition Examination Survey. Circulation 2004;110(16):2494–7.</mixed-citation></citation-alternatives></ref><ref id="B15"><label>15.</label><citation-alternatives><mixed-citation xml:lang="en">15. Israelian-Konaraki Z., Reaven P.D. Peroxisome proliferator-activated receptor-alpha and atherosclerosis: from basic mechanisms to clinical implications. Cardiology 2005;103(1):1–9.</mixed-citation><mixed-citation xml:lang="ru">Israelian-Konaraki Z., Reaven P.D. Peroxisome proliferator-activated receptor-alpha and atherosclerosis: from basic mechanisms to clinical implications. Cardiology 2005;103(1):1–9.</mixed-citation></citation-alternatives></ref></ref-list></back></article>
